As of March 2024, Stéphane Bancel owns approximately 30.1 million shares of Moderna, equating to about 7.7% of the company. His wealth peaked notably in 2021, aligning with the surge in COVID-19 vaccine sales, when the company's stock reached record...

As of March 2024, Stéphane Bancel owns approximately 30.1 million shares of Moderna, equating to about 7.7% of the company. His wealth peaked notably in 2021, aligning with the surge in COVID-19 vaccine sales, when the company's stock reached record highs. Bancel's holdings have shown fluctuations in value, demonstrating the ups and downs of the biotech market. His substantial ownership stake underlines the alignment of his interests with those of shareholders, as he benefits directly from the company's success. Bancel has consistently focused on growing his holdings, reflecting confidence in Moderna's future potential beyond just the COVID-19 vaccine.